The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
sitagliptin and metformin hydrochloride · SITAGLIPTIN PHOSPHATE 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 · Tablet, Film Coated, Extended Release · Oral · Par Health USA, LLC
NDC 10370-0351-11 · 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC · ANDA · View full market →
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00006-0081-31) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Zydus Lifesciences Limited | SITAGLIPTIN 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Zydus Lifesciences Limited | SITAGLIPTIN 50 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 50 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| A-S Medication Solutions | SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 | Aug 26, 2026 | Aug 31, 2026 |
| Zydus Lifesciences Limited | SITAGLIPTIN 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1 | Aug 26, 2026 | Aug 28, 2026 |
| Zydus Lifesciences Limited | SITAGLIPTIN 1000 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 23, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 500 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 25, 2026 | Aug 22, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 1000 mg/1; METFORMIN HYDROCHLORIDE 100 mg/1 | Jul 25, 2026 | Aug 22, 2026 |
| Par Health USA, LLC | SITAGLIPTIN PHOSPHATE 1000 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 25, 2026 | Aug 22, 2026 |
| Zydus Lifesciences Limited | SITAGLIPTIN 500 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 500 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Zydus Lifesciences Limited | SITAGLIPTIN 1000 mg/1; METFORMIN HYDROCHLORIDE 100 mg/1 | Jul 22, 2026 | Aug 21, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 1000 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 21, 2026 |
| A-S Medication Solutions | SITAGLIPTIN PHOSPHATE 1000 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 500 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 1000 mg/1; METFORMIN HYDROCHLORIDE 100 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Merck Sharp & Dohme LLC | SITAGLIPTIN PHOSPHATE 1000 mg/1; METFORMIN HYDROCHLORIDE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Zydus Pharmaceuticals USA Inc. | SITAGLIPTIN 1000 mg/1; METFORMIN HYDROCHLORIDE 100 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Zydus Lifesciences Limited | METFORMIN HYDROCHLORIDE 500 mg/1; SITAGLIPTIN 50 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Zydus Pharmaceuticals USA Inc. | METFORMIN HYDROCHLORIDE 500 mg/1; SITAGLIPTIN 50 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Zydus Pharmaceuticals USA Inc. | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN 100 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Zydus Lifesciences Limited | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN 100 mg/1 | Jul 15, 2026 | Jul 18, 2026 |
| Zydus Pharmaceuticals USA Inc. | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN 50 mg/1 | Jul 15, 2026 | Jul 18, 2026 |
| A-S Medication Solutions | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN PHOSPHATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Merck Sharp & Dohme LLC | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN PHOSPHATE 100 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Merck Sharp & Dohme LLC | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN PHOSPHATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Merck Sharp & Dohme LLC | METFORMIN HYDROCHLORIDE 500 mg/1; SITAGLIPTIN PHOSPHATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Zydus Lifesciences Limited | METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Sitagliptin and Metformin hydrochloride — NDC 10370-0351-11," retrieved September 3, 2026, https://drugdashboards.com/drug/10370035111.
Free to cite with attribution — see how the data is put together.